Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Most mechanistic/metabolite-related claims are not supported by the provided methocarbamol label excerpts and include interpretations about 'inactive metabolites' that are not addressed in the label text. Some general statements about metabolism/liver and elimination are not supported by the provided label. Overall alignment is poor.
Category Scores
Accurate Statements
Methocarbamol is a muscle relaxant.
Section 1 describes methocarbamol as an adjunct for relief of discomfort associated with acute painful musculoskeletal conditions; however, the provided excerpts do not explicitly state the phrase 'muscle relaxant' or 'directly relax tense skeletal muscles in man.'
Unsupported Statements
Methocarbamol is metabolized into other chemical forms (metabolites).
The provided label excerpts mention 'methocarbamol and/or its metabolites' (Nursing Mothers) but do not explicitly describe metabolism into metabolites; the statement is not directly supported by the provided text for general metabolism.
"Inactive metabolites" means those metabolites do not meaningfully produce the drug’s therapeutic effect compared with the parent drug (methocarbamol).
The term 'inactive metabolites' and its definition are not provided in the supplied labeling excerpts.
Inactive metabolites are primarily present as breakdown products rather than active contributors to muscle-relaxing pharmacology.
No labeling language in the provided excerpts characterizes metabolites as breakdown products or addresses their role in muscle-relaxing pharmacology.
The term "inactive metabolites" is used when metabolite(s) formed after dosing have little or no muscle-relaxant activity in pharmacodynamic testing.
No pharmacodynamic testing description or definition of 'inactive metabolites' is present in the provided label excerpts.
The term "inactive metabolites" is used when there is no strong evidence they contribute to the clinical effects in humans.
The provided label does not define or discuss 'inactive metabolites' in terms of evidence in humans for clinical effects.
The presence of inactive metabolites is distinct from metabolites that are known to be active and are a major driver of efficacy.
No discussion in the provided excerpts distinguishes active vs inactive metabolites or links metabolites to efficacy.
Methocarbamol is processed by the liver.
The provided labeling excerpts do not state that methocarbamol is processed/metabolized by the liver.
Methocarbamol is eliminated from the body after metabolism.
The provided excerpts do not describe elimination following metabolism; they only mention (in Nursing Mothers) excretion in dogs’ milk and unknown excretion in human milk.
If methocarbamol’s metabolites are inactive, then dose changes and drug effects depend more on methocarbamol itself than on "metabolite activity."
The label does not discuss dose-effect dependence on metabolite activity.
If methocarbamol’s metabolites are inactive, conditions that affect methocarbamol metabolism (for example, severe liver impairment) could still change drug exposure and side effects.
The provided excerpts do not discuss severe liver impairment, metabolism, or exposure/side effect changes based on metabolite inactivity.
If methocarbamol’s metabolites are inactive, drug interactions that slow or speed methocarbamol metabolism can alter how long methocarbamol stays active in the body.
The provided excerpts do not describe interactions via effects on methocarbamol metabolism or changes in duration of action based on metabolism.
Contradictions
Important Omissions
The label states: 'Methocarbamol does not directly relax tense skeletal muscles in man.' The AI framing of 'muscle relaxant pharmacology' and metabolite contribution could imply direct muscle-relaxing activity that is not supported by the provided label excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern metabolite definitions/mechanistic interpretations not present in the provided label. No direct dosing, contraindication, boxed warning, or concrete harmful instruction conflicts with label excerpts were identified from the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple mechanistic/metabolite-related assertions (definition of 'inactive metabolites', role in efficacy, liver processing, elimination, and interaction effects on metabolism/duration) are not supported by the provided FDA-approved labeling excerpts.
Suggested Improvement
Limit statements to label-supported concepts in the provided excerpts (e.g., adjunct indication; general CNS depressant effects and cautions with alcohol/CNS depressants; specific interaction with pyridostigmine in myasthenia gravis; pregnancy/nursing/pediatric cautions). Remove or rephrase metabolite mechanism/duration-of-action claims unless the provided label text explicitly supports them.